Insider · CIK 0001788542
Aziz Mottiwala
Files at TARS (Tarsus Pharmaceuticals, Inc.). First filing Jun 11, 2025, latest Mar 19, 2026.
Aziz Mottiwala files SEC Form 4 as officer at TARS (Tarsus Pharmaceuticals, Inc.). Since Jun 11, 2025, Aziz Mottiwala has reported 0 open-market buys worth $0 and 2 open-market sells worth $1.7M, the latest filed on Mar 19, 2026.
A track record needs three past buys with six months of prices behind them; Aziz Mottiwala has 0, so none is measured yet.
The newest scored trade: sold $893k of TARS on Mar 17, 2026, filed Mar 19, 2026, scored 58 (moderate). In the last 12 months: 0 buys worth $0 and 1 sell worth $893k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
TARS: Tarsus Pharmaceuticals, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 58Moderate | Tarsus Pharmaceuticals, Inc. | $893k 13,056 shares | -18% | +80% from low-15% from high | |
| 42Moderate | Tarsus Pharmaceuticals, Inc. | $766k 17,500 shares | -27% | +39% from low-24% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Mar 19, 2026 | TARS Tarsus Pharmaceuticals, Inc. | 4,440 0.01% of outstanding | $297k | Mar 19, 2026 | $595k |
| Mar 18, 2026 | TARS Tarsus Pharmaceuticals, Inc. | 4,330 0.01% of outstanding | $298k | Mar 18, 2026 | $298k |
| Mar 17, 2026 | TARS Tarsus Pharmaceuticals, Inc. | 4,286 0.01% of outstanding | $298k | Mar 17, 2026 | none |
| Jun 9, 2025 | TARS Tarsus Pharmaceuticals, Inc. | 17,500 0.04% of outstanding | $783k | Jun 9, 2025 | $506k |
| Mar 20, 2025 | TARS Tarsus Pharmaceuticals, Inc. | 3,365 0.01% of outstanding | $169k | Mar 20, 2025 | $337k |
| Mar 19, 2025 | TARS Tarsus Pharmaceuticals, Inc. | 3,557 0.01% of outstanding | $169k | Mar 19, 2025 | $169k |
| Mar 18, 2025 | TARS Tarsus Pharmaceuticals, Inc. | 3,643 0.01% of outstanding | $169k | Mar 18, 2025 | none |
Transactions
Every row this insider has filed, 11 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 17, 2026 | TARS Tarsus Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -4,286 | $69.42 | $298k | 70,250 | Mar 19, 2026 |
| Mar 18, 2026 | TARS Tarsus Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -4,330 | $68.71 | $298k | 65,920 | Mar 19, 2026 |
| Mar 19, 2026 | TARS Tarsus Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -4,440 | $67.00 | $297k | 61,480 | Mar 19, 2026 |
| Mar 15, 2026 | TARS Tarsus Pharmaceuticals, Inc. | MOption exercise Common Stock | +26,482 | - | - | 74,536 | Mar 17, 2026 |
| Mar 15, 2026 | TARS Tarsus Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -4,790 | $0.00 | $0 | 0 | Mar 17, 2026 |
| Mar 15, 2026 | TARS Tarsus Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -8,148 | $0.00 | $0 | 8,148 | Mar 17, 2026 |
| Mar 15, 2026 | TARS Tarsus Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -8,020 | $0.00 | $0 | 16,040 | Mar 17, 2026 |
| Mar 15, 2026 | TARS Tarsus Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -5,524 | $0.00 | $0 | 16,574 | Mar 17, 2026 |
| Mar 5, 2026 | TARS Tarsus Pharmaceuticals, Inc. | AGrant or award Stock Option (right to buy)derivative | +30,724 | $0.00 | $0 | 30,724 | Mar 9, 2026 |
| Mar 5, 2026 | TARS Tarsus Pharmaceuticals, Inc. | AGrant or award Restricted Stock Unitsderivative | +19,306 | $0.00 | $0 | 19,306 | Mar 9, 2026 |
| Jun 9, 2025 | TARS Tarsus Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -17,500 | $43.76 | $766k | 47,557 | Jun 11, 2025 |
Questions about Aziz Mottiwala
Answered from the filings on this page, as of the latest one.
Is Aziz Mottiwala buying or selling?
In the last 12 months Aziz Mottiwala reported 0 open-market buys worth $0 and 1 open-market sell worth $893k on SEC Form 4; the latest was sold $893k of TARS on Mar 17, 2026. Grants, option exercises and tax withholding are not counted.
How did Aziz Mottiwala's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Aziz Mottiwala has 0.
Where does Aziz Mottiwala file Form 4?
Aziz Mottiwala has filed Form 4 at TARS (Tarsus Pharmaceuticals, Inc.) as Chief Commercial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.